<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Oberheiden P.C. by Janie Yow</title>
      <link>https://padlet.com/janieyow/1butlze9zq0ad1dt</link>
      <description></description>
      <language>en-us</language>
      <pubDate>2024-07-16 06:08:12 UTC</pubDate>
      <lastBuildDate>2024-07-16 06:08:46 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Find out more
</title>
         <author>janieyow</author>
         <link>https://padlet.com/janieyow/1butlze9zq0ad1dt/wish/3054443599</link>
         <description><![CDATA[<p>Ozempic is the brand name for a drug that uses semaglutide to treat type 2 diabetes. Its efficacy to cause weight loss were well known, and a couple of years ago its manufacturer, Novo Nordisk, tinkered with the dosing and got the U.S. Food and Drug Administration (FDA) to approve the new drug, called Wegovy, as a weight loss drug. After a huge marketing campaign, the new semaglutide drug because incredibly popular.</p><p><br/></p>]]></description>
         <enclosure url="https://federal-lawyer.com/ozempic/" />
         <pubDate>2024-07-16 06:08:46 UTC</pubDate>
         <guid>https://padlet.com/janieyow/1butlze9zq0ad1dt/wish/3054443599</guid>
      </item>
   </channel>
</rss>
